Using Fibroscan to Predict Immunotherapy Response in Advanced Hepatocellular Carcinoma Patients

What this Trial Is About

Researchers are evaluating the use of transient elastography Fibroscan to predict how patients with advanced Hepatocellular Carcinoma HCC respond to immunotherapy. The study aims to assess changes in liver fibrosis, liver decompensation, complications, survival, and mortality over a 6-month treatment period. This observational study focuses on patients with advanced HCC who are eligible for immunotherapy and have preserved liver function. Participants will undergo a range of assessments at the start of the study, including medical history, clinical exams, lab tests, liver function classifications Child-Pugh and MELD scores, cancer staging BCLC, abdominal ultrasound, imaging studies Triphasic CT or MRI, and Fibroscan to measure liver stiffness. After 6 months of immunotherapy, patients will return for follow-up visits involving laboratory tests, evaluation of treatment side effects, imaging, and another Fibroscan exam to monitor changes. During the study, researchers will track liver stiffness changes as the primary outcome over about one year. Secondary outcomes include rates of liver decompensation and mortality at 6 months. Participants will be monitored through clinic visits, imaging, and laboratory evaluations to assess their response to immunotherapy and overall health status. The total participation duration includes baseline assessments and a 6-month follow-up period.

Fibroscan Evaluating Immunotherapy Response in Hepatocellular Carcinoma